IRIS
CAMELI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 14.678
NA - Nord America 14.171
AS - Asia 8.044
SA - Sud America 1.416
AF - Africa 509
OC - Oceania 42
Continente sconosciuto - Info sul continente non disponibili 9
AN - Antartide 1
Totale 38.870
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.834
IT - Italia 4.064
RU - Federazione Russa 3.295
SG - Singapore 2.665
CN - Cina 1.877
GB - Regno Unito 1.826
IE - Irlanda 1.658
BR - Brasile 1.170
VN - Vietnam 1.048
DE - Germania 847
HK - Hong Kong 808
SE - Svezia 741
FR - Francia 681
FI - Finlandia 510
IN - India 377
KR - Corea 307
ZA - Sudafrica 272
BD - Bangladesh 218
UA - Ucraina 202
NL - Olanda 196
CA - Canada 181
ES - Italia 164
JP - Giappone 114
IQ - Iraq 103
MX - Messico 100
PL - Polonia 98
CZ - Repubblica Ceca 78
TR - Turchia 70
CI - Costa d'Avorio 62
AR - Argentina 60
AT - Austria 60
PK - Pakistan 59
EC - Ecuador 49
ID - Indonesia 45
NG - Nigeria 44
IR - Iran 41
SA - Arabia Saudita 39
CH - Svizzera 36
VE - Venezuela 36
KE - Kenya 35
BE - Belgio 34
AU - Australia 32
PH - Filippine 31
MA - Marocco 30
UZ - Uzbekistan 29
LT - Lituania 26
AE - Emirati Arabi Uniti 25
CO - Colombia 25
CL - Cile 22
MY - Malesia 20
EG - Egitto 19
PY - Paraguay 19
JO - Giordania 18
PE - Perù 18
AZ - Azerbaigian 16
DK - Danimarca 16
HU - Ungheria 15
PT - Portogallo 15
BG - Bulgaria 14
IL - Israele 14
RO - Romania 14
TN - Tunisia 14
KZ - Kazakistan 13
AL - Albania 12
DZ - Algeria 12
JM - Giamaica 11
LB - Libano 11
NP - Nepal 11
PA - Panama 10
BO - Bolivia 9
GR - Grecia 9
KG - Kirghizistan 9
GE - Georgia 8
MK - Macedonia 8
NZ - Nuova Zelanda 8
OM - Oman 8
BY - Bielorussia 7
CY - Cipro 7
EE - Estonia 7
LV - Lettonia 7
PS - Palestinian Territory 7
SN - Senegal 7
CR - Costa Rica 6
EU - Europa 6
LA - Repubblica Popolare Democratica del Laos 6
LK - Sri Lanka 6
UY - Uruguay 6
DO - Repubblica Dominicana 5
HR - Croazia 5
NO - Norvegia 5
QA - Qatar 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
TH - Thailandia 5
AM - Armenia 4
HN - Honduras 4
KW - Kuwait 4
LU - Lussemburgo 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
Totale 38.806
Salva come PNG Salva come JPEG
Città #
Dallas 2.905
Dublin 1.627
Singapore 1.567
Southend 1.442
Ashburn 1.086
Moscow 991
San Jose 952
Santa Clara 912
Hong Kong 752
Fairfield 731
Chandler 716
Milan 679
Siena 494
Beijing 483
Hefei 455
Los Angeles 398
Council Bluffs 371
Munich 368
Helsinki 340
Woodbridge 321
Ho Chi Minh City 318
Lastra a Signa 314
Houston 307
Wilmington 306
New York 298
Florence 281
Seoul 280
Seattle 270
Rome 267
Johannesburg 243
Hanoi 239
Princeton 230
Cambridge 229
Lauterbourg 222
The Dalles 170
Ann Arbor 146
São Paulo 117
Jacksonville 110
Chicago 98
Shanghai 98
Orem 91
Buffalo 86
Redondo Beach 85
Tokyo 85
Bengaluru 83
Warsaw 82
Frankfurt am Main 77
San Mateo 76
Turku 76
Dong Ket 75
Lappeenranta 73
London 72
San Diego 72
Fremont 71
Málaga 68
Nuremberg 63
Abidjan 62
Boardman 61
Chennai 61
Düsseldorf 59
Da Nang 54
Montreal 54
Portsmouth 52
Dearborn 51
Phoenix 50
Atlanta 48
Toronto 48
Stockholm 47
Brno 44
Brooklyn 44
Rio de Janeiro 44
Naples 40
Haiphong 39
Manchester 39
Denver 38
Washington 37
Baghdad 36
Turin 36
Amsterdam 34
Boston 34
Poplar 34
Abuja 33
Mexico City 32
Brescia 31
Guangzhou 31
Vienna 31
Bologna 30
San Francisco 30
Dhaka 28
Paris 27
Figino 26
Gavirate 26
Tashkent 26
Brasília 25
Newark 25
Mumbai 24
Olomouc 24
Padova 24
Piscataway 24
Salt Lake City 24
Totale 25.035
Salva come PNG Salva come JPEG
Nome #
A first update on mapping the human genetic architecture of COVID-19 583
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 577
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 516
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 505
Genetic mechanisms of critical illness in COVID-19 432
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 425
An explainable model of host genetic interactions linked to COVID-19 severity 371
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 356
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 356
Pathogen-sugar interactions revealed by universal saturation transfer analysis 355
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 344
null 320
Peripheral biomarkers' panel for severe COVID-19 patients 319
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 314
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 308
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 299
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 298
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 298
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 294
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 291
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 285
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 282
ACUTE HF score, a multiparametric prognostic tool for acute heart failure: A real-life study 275
Exhaled nitric oxide in interstitial lung diseases 274
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 274
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 266
The impact of antifibrotic therapy in the management of idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases: a real-world comparative study of efficacy between pirfenidone and nintedanib 262
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 261
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 259
Prognostic bioindicators in severe COVID-19 patients 257
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 256
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 251
Serial KL-6 measurements in COVID-19 patients 250
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 249
Omalizumab treatment in Samter's triad: case series and review of the literature 248
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 247
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 247
Incremental value of pocket-sized imaging device for bedside diagnosis of unilateral pleural effusions and ultrasound-guided thoracentesis 246
Serum amyloid A in patients with idiopathic pulmonary fibrosis 242
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 242
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 237
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 237
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 237
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 233
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 232
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 230
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 229
NK and NKT-like cells in granulomatous and fibrotic lung diseases 228
Comparison of Right Versus Left Ventricular Strain Analysis as a Predictor of Outcome in Patients With Systolic Heart Failure Referred for Heart Transplantation 228
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 227
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 226
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 223
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 223
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 222
Cor pulmonale: the role of traditional and advanced echocardiography in the acute and chronic settings 222
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 221
Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19 219
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 217
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 215
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 214
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 213
Portable Pocket-Sized Ultrasound Scanner for the Evaluation of Lung Involvement in Coronavirus Disease 2019 Patients 213
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 212
Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence 210
Whole-genome sequencing reveals host factors underlying critical COVID-19 206
WES profiling of COVID-19 206
Serum amyloid A: A potential biomarker of lung disorders 203
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 203
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 201
Severe asthma and long-term Benralizumab effectiveness in real-life 197
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 197
Traditional and Novel Imaging of Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction 195
Effects of rituximab therapy on B cell differentiation and depletion 194
Right cardiac involvement in lung diseases: a multimodality approach from diagnosis to prognostication 194
Clinical and molecular characterization of COVID-19 hospitalized patients 194
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 192
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 191
Basic and advanced echocardiography in advanced heart failure: an overview 190
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 190
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 189
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 184
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 184
Left atrial strain as a pre-operative prognostic marker for patients with severe mitral regurgitation 184
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 182
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 182
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 182
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 179
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 179
The Effects of Interstitial Lung Diseases on Alveolar Extracellular Vesicles Profile: A Multicenter Study 178
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 178
Timing of Osteoporotic Vertebral Fractures in Lung and Heart Transplantation: A Longitudinal Study 177
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a new protocol for investigating the mechanisms of idiopathic pulmonary fibrosis 175
Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study 174
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 174
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 174
Bone fragility and sarcoidosis: An underestimated relationship 173
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 172
Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker? 169
Markers of Bronchiolitis Obliterans Syndrome after Lung Transplant: Between Old Knowledge and Future Perspective 168
Immunologic responses to antifibrotic treatment in IPF patients 167
Totale 24.779
Salva come PNG Salva come JPEG
Categoria #
all - tutte 133.688
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 133.688
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021228 0 0 0 0 0 0 0 0 0 0 0 228
2021/20222.553 187 281 225 182 124 114 110 118 114 321 269 508
2022/20233.028 200 342 390 305 186 521 261 265 210 123 127 98
2023/20243.392 132 93 328 173 170 737 956 193 56 119 127 308
2024/20257.932 607 312 846 453 960 485 452 458 644 394 729 1.592
2025/202618.726 1.279 2.445 2.254 2.176 3.399 642 2.287 600 739 1.305 708 892
Totale 39.872